Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607892 · ClinicalTrials.gov registry record · Phase 1
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
A Phase 1 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 286
- Enrollment target
NCT01607892 is a Phase 1 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 286 participants.
The verdict
NCT01607892, a Phase 1 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 286 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the effects of KCP-330 on the body (pharmacodynamics or PDn) and to obtain information on its effectiveness in treating cancer.
Interventions
- DRUG KPT-330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2012-07-23 |
| Est. Completion | 2015-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01607892
The ClinicalTrials.gov registry entry for NCT01607892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KPT-330 is the first listed.
NCT01607892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01607892 about?
NCT01607892 is a clinical study titled "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer". The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the effects of KCP-330 on the bo...
What is the current status of trial NCT01607892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 286 participants. The study started on 2012-07-23. Estimated completion is 2015-10-13.
What interventions are being tested in trial NCT01607892?
The interventions under investigation include: KPT-330 (DRUG).
Who is sponsoring clinical trial NCT01607892?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.